Navigation Links
Akela Pharma provides corporate update
Date:12/20/2007

http://www.akelapharma.com Toronto Stock Exchange Symbol: AKL

MONTREAL, Dec. 20 /PRNewswire-FirstCall/ - Akela Pharma Inc. (TSX: "AKL"), a drug development company focused on developing therapies for the inhalation and pain markets, today announced that due to unfavorable market conditions, particularly in the small and micro-cap sector, it has decided to abandon its US public offering initiative. The Company is currently contemplating other financing options. It is still the Company's intention to list its shares on a US exchange.

Akela also announces it has already started to implement significant cost reduction measures to bring its cash burn rate in line with its current and expected financial resources. The Company will primarily focus its R&D activities on its core programs. PharmaForm, the Company's drug formulation and manufacturing subsidiary located in Austin, Texas, is currently experiencing substantial growth, and is expected to contribute towards the Company's operating cash flow in the near term.

"Although the latest unfavorable market conditions did not allow us to complete our US public offering as originally planned, we remain extremely confident about the appeal and commercial potential of our products and platforms. We have aligned our corporate focus with our financial resources to ensure optimal returns on our core activities" said Dr Halvor Jaeger, CEO of Akela Pharma Inc.

About Akela Pharma Inc.

Akela Pharma is an integrated drug development company focused on developing therapies for the growing multi-billion dollar inhalation and pain markets. Its lead product, for the treatment of breakthrough cancer pain, is a fast-acting Fentanyl formulation delivered using the Company's TAIFUN(R) dry powder inhaler platform. Its pipeline also includes therapeutics for asthma, COPD, growth hormone deficiencies and controlled substance abuse deterrent fo
'/>"/>

SOURCE AKELA PHARMA INC.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. AKELA Pharma Inc. announces positive results for the extension part of its Phase IIb Fentanyl TAIFUN(R) trial
2. Akela Pharma Inc. Completes Share Consolidation
3. AKELA Pharma Inc. announces U.S. public offering and proposed listing
4. Akela Pharma reports results for third quarter of fiscal 2007
5. Akela Pharma announces final positive results from its growth hormone releasing hormone (GHRH) Phase II trial
6. Anemia and tropical diseases; Is pharmacogenomics ready for the clinic?
7. Mylan Commences Tender Offers and Consent Solicitations for Its 5.750% Senior Notes Due 2010 and 6.375% Senior Notes Due 2015 in Connection With Its Proposed Acquisition of Mercks Generic Pharmaceutical Business
8. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
9. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
10. The Pharma & Life Sciences Best Practice Database: an Industry Resource for Successful Techniques and Performance Benchmarks for Reaching the Top
11. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/2/2015)... March 02, 2015 ProvidaStaff ... for its educational healthcare division to EDU Healthcare ... healthcare services to school systems and students nationwide. , ... to school districts throughout the country,” said Angela M. ... be a better organization and the introduction of EDU ...
(Date:3/2/2015)... California (PRWEB) March 02, 2015 Final ... of the TranStatic Volume 2 from Pixel Film Studios. , ... made exclusively for FCPX,” said Christina Austin, CEO of Pixel ... have in any Final Cut Pro X editors toolbox.” , ... to the next with media altering static scrambling effects from ...
(Date:3/1/2015)... 2015 To help healthcare ... their practices compliantly and profitably, MDreferralPRO and ... The interoperability between a strategic referral ... practice management system is necessary for a ... A referral management and development solution relies ...
(Date:3/1/2015)... As residents and business owners ... Burns and Carita Weaver, believe in supporting local ... the Southlake Chamber of Commerce, Carroll Independent School ... launched a website for Southlake mayoral candidate Laura ... tool for Hill’s campaign, the website combines images, ...
(Date:3/1/2015)... Birmingham, Clarkston, Lake Orion, Metamora, Michigan (PRWEB) March 01, 2015 ... BOTOX® , which is approved to treat Overactive Bladder (OAB) ... urgency and frequency in adults when another type of medication ... This is a different treatment option that takes another ... itself. , BOTOX® works on the nerves and ...
Breaking Medicine News(10 mins):Health News:ProvidaStaff Announces New Name Change to EDU Healthcare for Its Educational Healthcare Division 2Health News:ProvidaStaff Announces New Name Change to EDU Healthcare for Its Educational Healthcare Division 3Health News:Pixel Film Studios released the TranStatic Volume 2 plugin for Final Cut Pro X today 2Health News:Power Up Physician and Patient Referral Management While Qualifying for ARRA Incentives 2Health News:Power Up Physician and Patient Referral Management While Qualifying for ARRA Incentives 3Health News:Power Up Physician and Patient Referral Management While Qualifying for ARRA Incentives 4Health News:Website Launched for Southlake, Texas Mayoral Candidate Laura Hill 2Health News:Women's Excellence Now Offers BOTOX For Overactive Bladder Treatment 2
... ... Company, a leading supplier of industrial and technical parts and free CAD images ... input from their customers. John Carrier, the company,s President, says the new ReidSupply.com ... and a de-emphasis on marketing. The new site takes the customer exactly where ...
... during a Caesarean section helps manage pain after the ... Cochrane Researchers. The researchers recommend local anaesthetics as part ... provided that consideration is given to the cost. ... the growing number of women giving birth by Caesarean ...
... , LOS ANGELES, July 7 /PRNewswire-USNewswire/ -- A ... upcoming "Be a Hero for Babies Day" to raise funds ... moms have full-term pregnancies and healthy babies. , , Make a ... and the gift will double in value thanks to ...
... for U.S. research dollars, NIH says , MONDAY, July ... guidelines Monday describing which embryonic stem cell lines will ... of stem cells that can be used for research. ... that embryonic stem cells used in research were obtained ...
... Laboratories, a national clinical and anatomic pathology reference laboratory ... announced today the appointment of Sherrie L. Perkins, MD, ... laboratories, effective, July 1, 2009. , , Dr. ... R. Ashwood, MD, who will be transitioning into the ...
... Eli Lilly and Company (NYSE: LLY ) will ... Wednesday, July 22, 2009. Lilly will also conduct a conference ... further detail the company,s financial performance. , , The ... EDT. Investors, media and the general public can access a ...
Cached Medicine News:Health News:Customers Design Reid Supply's New Web Site 2Health News:Customers Design Reid Supply's New Web Site 3Health News:Customers Design Reid Supply's New Web Site 4Health News:Customers Design Reid Supply's New Web Site 5Health News:Farmers Insurance Pledges to Match All Donations Up to $250k For "Be a Hero for Babies Day" to Benefit March Of Dimes 2Health News:Final Rules Broaden Pool for Stem Cell Research 2Health News:Final Rules Broaden Pool for Stem Cell Research 3Health News:Final Rules Broaden Pool for Stem Cell Research 4Health News:ARUP Laboratories Announces New CMO Appointment 2
(Date:3/2/2015)... -- According to statistics released by the American Society of ... fillers, such as the JUVEDERM ® family of fillers ... between 2013 to 2014, HA filler treatments increased by 8 ... which shows U.S. unit sales of HA dermal fillers were ... "These findings are consistent with what I see every day ...
(Date:3/2/2015)... , March 2, 2015 Cardinal Health today ... a leading global manufacturer of cardiology and endovascular devices, ... net of the present value of tax benefits. The ... of $1.0 billion in new senior unsecured notes and ... to close in the United States ...
(Date:3/2/2015)... and BETHESDA, Md. , March ... company focused on treating and preventing autoimmune diseases, announced ... monoclonal antibody (AMG 714) from Amgen (NASDAQ: ... agreement, Celimmune has the rights to develop, manufacture and ... Japan . Concurrently, Amgen has been granted ...
Breaking Medicine Technology:Demand For Hyaluronic Acid Facial Fillers In The U.S. Increases By 8 Percent 2Demand For Hyaluronic Acid Facial Fillers In The U.S. Increases By 8 Percent 3Demand For Hyaluronic Acid Facial Fillers In The U.S. Increases By 8 Percent 4Demand For Hyaluronic Acid Facial Fillers In The U.S. Increases By 8 Percent 5Demand For Hyaluronic Acid Facial Fillers In The U.S. Increases By 8 Percent 6Demand For Hyaluronic Acid Facial Fillers In The U.S. Increases By 8 Percent 7Cardinal Health To Acquire Cordis, A Worldwide Leader In Cardiac And Endovascular Medical Products For $1.944 Billion In Cash 2Cardinal Health To Acquire Cordis, A Worldwide Leader In Cardiac And Endovascular Medical Products For $1.944 Billion In Cash 3Cardinal Health To Acquire Cordis, A Worldwide Leader In Cardiac And Endovascular Medical Products For $1.944 Billion In Cash 4Cardinal Health To Acquire Cordis, A Worldwide Leader In Cardiac And Endovascular Medical Products For $1.944 Billion In Cash 5Cardinal Health To Acquire Cordis, A Worldwide Leader In Cardiac And Endovascular Medical Products For $1.944 Billion In Cash 6Cardinal Health To Acquire Cordis, A Worldwide Leader In Cardiac And Endovascular Medical Products For $1.944 Billion In Cash 7Celimmune Announces Anti-IL-15 Antibody Licensing and Option Agreements with Amgen 2Celimmune Announces Anti-IL-15 Antibody Licensing and Option Agreements with Amgen 3
... OTI's new Spectral system is a combination ... Laser Ophthalmoscope (SLO) system that provides suberb, ... choroidal-retina structure. With the advancements of spectral ... of up to 27,000 A-Scans per second ...
... Arctic Circler uses the same cryoconsole ... AF originating in the pulmonary veins. Arctic ... challenge the traditional palliative-only treatments that rely ... the Arctic Circler catheter has the ability ...
The KMedic Jet Wire Twister is designed to provide fast, smooth and even twisting of soft wire, saving time in the O.R. Now available for the first time in stainless steel. Suitable for the entire ra...
Osteophyte periosteal elevator for bone removing....
Medicine Products: